drugset / Trial / NCT05733286

REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant

NCT05733286

Phase 2 Completed 142 enrolled Duke University Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This research study will evaluate the effectiveness of postoperative administration of a drug called suvorexant, to improve postoperative sleep and decrease the severity of delirium (serious confusion) in adults 65 years and older undergoing non-cardiac surgery.

Timeline

Start
2023-06-28
Primary completion
2025-06-25
Completion
2025-07-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Suvorexant Small molecule 20 mg Oral

Indications